Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy

Pharmacogenomics

Volumn 13, Issue 4, 2012, Pages 419-427

  Li, Yan ^a   Yang, Shu Ying ^a   Kang, Shan ^a   Yip, Benjamin H K ^b   Zhou, Rong Miao ^a   Wang, Na ^a   Sun, Hai Yan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

19007T C SNP; 8092C A SNP; epithelial ovarian cancer; ERCC1; platinum chemotherapy; SNP

Indexed keywords

PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CHINESE; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIAL OVARIAN CANCER; ERCC1 GENE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL TIME;

ADULT; BIOMARKERS, PHARMACOLOGICAL; CHINA; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84863252577     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.181     Document Type: Article

References (33)

1. Meijiao G, Wei S. Current research and management of ovarian cancer in China. Chinese-German J. Clin. Oncol. 1, 212-218 (2002).
2. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351 (24), 2519-2529 (2004).
3. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int. J. Mol. Med. 14, 959-970 (2004).
4. Harper P. Current clinical practices for ovarian cancers. Semin. Oncol. 29, 3-6 (2002).
5. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24, 331-344 (1998).
6. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer. Res. 11, 6100-6102 (2005).
7. Enzlin JH, Scharer OD. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J. 21, 2045-2053 (2002).
8. Li Q, Yu JJ, Mu C et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 20, 645-652 (2000).
9. Ren S, Zhou S, Zhang L et al. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest. 28, 1078-1083 (2010).
10. Jun HJ, Ahn MJ, Kim HS et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br. J. Cancer 99, 167-172 (2008).
11. Yu JJ, Mu C, Lee KB et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 382, 13-20 (1997).
12. Chen P, Wiencke J, Aldape K et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 9, 843-847 (2000).
13. Park SY, Hong YC, Kim JH et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of nonsmall cell lung cancer patients. Med. Oncol. 23, 489-498 (2006).
14. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27, 3540-3546 (2009).
15. Krivak TC, Darcy KM, Tian C et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J. Clin. Oncol. 26, 3598-3606 (2008).
16. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25, 4528-4535 (2007).
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
19. Markman M. Decision-making in the management of recurrent epithelial ovarian cancer. In: Gynecologic cancer: Controversies in Management. Gershenson DM (Ed.). Churchill Livingstone, London, UK, 447-454 (2004).
20. Miller SA, Dybes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
21. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194-1203 (2004).
22. Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11, 6212-6217 (2005).
23. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91, 344-354 (2004).
24. Kang S, Ju W, Kim JW et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp. Mol. Med. 38, 320-324 (2006).
25. Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int. J. Gynecol. Cancer 18, 702-710 (2008).
26. Smith S, Su D, Rigault de la Longrais IA et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol. 25, 5172-5179 (2007).
27. Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat. Res. 708, 21-27 (2011).
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
29. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10, 54-61 (2010).
30. Chan JK, Tian C, Teoh D et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 116, 307-311 (2010).
31. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology 11, 95-105 (1997).
32. Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113, 264-269 (2009).
33. Krivak TC, Darcy KM, Tian C et al. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol. Oncol. 122, 121-126 (2011).